PERSEE

Every edition, the free report included, names who said each statement, as the source shows them. Each named voice's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 44 of the 64 cited voices have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key. The verified speaker identities add-on, sold with 12-month plans, adds each verified person's IDs as data (the NPI number, X, Bluesky and LinkedIn accounts, ORCID and institutional pages), so your team can check each attribution itself. It is for checking attribution inside your organization, never for outreach or targeting, and it does not unlock who said what.

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

Screened window

Jan 22, 2021 → Nov 1, 2026

Cited window

Jan 31, 2021 → Nov 1, 2026

Retrieved

Nov 3, 2026

Title

Randomized, Open-label, Controlled Phase III Trial Comparing Pembrolizumab-platinum Based Chemotherapy Combination With Pembrolizumab Monotherapy in First Line Treatment of Non-small-cell Lung Cancers (NSCLC) With PDL1 Expression ≥50%

Registry

NCT04547504

Study IDs

29BRC20.0159_GFPC01-2020 · GFPC 01-2020 (Groupe Français de Pneumo-Cancérologie)

Sponsor

University Hospital, Brest

Collaborators

Groupe Francais De Pneumo-Cancerologie

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

349 actual

Registered

2020-09-14

Start

2020-12-22 actual

Primary completion

2025-12-22 estimated

Primary endpoint

Progression-free survival (PFS) according to RECIST 1.1 assessed by blinded inependant centra review (BICR)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –1 matching source (1 X thread) could not be read and is not included.
• –Not yet captured in this edition: a view on first-line treatment selection, the limited role of added immunotherapy, and concerns about patient selection in prior evidence.
• –2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –182 passages in 80 sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –63 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; 33 sources about other trials or topics are not included.
• –The sources reviewed are not a representative sample of all HCPs. Some discussions were not fully assessed, one identified discussion could not be read, and unnamed or differently transcribed references may be absent.
• –Several organizational summaries, repeated posts and secondary relays describe the same presentation or publication. Their number cannot be interpreted as the number of independent clinicians endorsing a view.
• –The AI-voiced episode does not establish a named clinician as its narrator. “Rafael” is known only by first name in the relevant passage.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Sources describe some contributors' involvement in PERSEE, but those descriptions are not independent confirmation of trial roles and do not increase the evidentiary weight of their opinions.
• –Accounts conflict over primary-endpoint achievement, premature stopping and one interview PFS median. These discrepancies remain visible rather than being silently reconciled.
• –OS superiority is not established in the reported comparison; insufficient power and subsequent treatment complicate interpretation but do not prove either benefit or absence of benefit.
• –Subgroup, comutation and biomarker interpretations are often exploratory or proposed. Age, histology, sex and molecular features discussed here should not be read as validated treatment-selection rules.
• –Earlier indirect comparisons, retrospective analyses, PAULIEN and alternative-regimen discussions retain their own study, setting and timing; they are not PERSEE outcomes.
• –Full protocol and regulatory-label text were not available. The report cannot resolve every statistical-plan question or establish label compatibility.
• –The available statements do not resolve the requested quality-of-life, detailed molecular, subsequent-treatment or economic questions.

How reports are built and checked: Methods.

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes how the published edition states something, such as a count, a name or a sentence, without making a new edition, so the version stays the same. Every correction is listed here with its date. Last checked for new commentary Nov 3, 2026 UTC. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "PERSEE" (NCT04547504), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "persee-nct04547504". If you cannot make requests, read https://www.erudio.com/reports/persee-nct04547504.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT04547504", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT04547504 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/persee-nct04547504.json
curl https://www.erudio.com/reports/persee-nct04547504.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "persee-nct04547504" })